(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
最近の投稿
- 1
Earth’s magnetic field protects life on Earth from radiation, but it can move, and the magnetic poles can even flip - 2Hunger and makeshift shelters persist in north Caribbean nearly 2 months after Hurricane Melissa
- 36 Solid Moving Administrations for a Calm Movement
- 4Vaccine committee votes to scrap universal hepatitis B shots for newborns despite outcry from children’s health experts
- 5Doggie diversity in size and shape began at least 11,000 years ago
- Why this Iranian island looks like Mars after it rains
- IDF destroys two-kilometer-long Gaza terror tunnel in Beit Lahiya
- Lego's $650 Pokémon set is already sold out as demand, preorders surge
- Step by step instructions to Deal with Your Time While Chasing after an Internet based Degree
- Vote in favor of your #1 sort of juice
- South America's Memorable Destinations: A Movement Guide
- Unwind: Four Extraordinary Spa Resorts On the planet
- AstraZeneca to invest $2 billion as part of US manufacturing push
- The Best Internet Mastering Stages for Expertise Improvement
